A technology platform to assess multiple cancer agents simultaneously within a patient’s tumor
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Simultaneous in vivo assessment of multiple cancer drugs and drug combinations using microinjection technology predicts systemic response in model tumors and has shown feasibility for assessment of drug efficacy in a pilot study in cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
limma: Linear Models for Microarray Data
Smyth, G. K. (2005) · Statistics for Biology and Health · doi:10.1007/0-387-29362-0_23 · Cited by 5,796
TM4: a free, open-source system for microarray data management and analysis
Saeed, A. I., Sharov, V., White, J., Li, J., Liang, W., Bhagabati, N., Braisted, J., Klapa, M., Currier, T., Thiagarajan, M., et al. (2003) · BioTechniques · doi:10.2144/03342mt01 · Cited by 4,837
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167 · cited 1×
“Attrition rates for new oncology drugs in clinical trials are higher than those of almost all other therapeutic areas, and survival rates for patientswith advanced cancers are persistently low (1, 2).”
Drug Resistance and the Solid Tumor Microenvironment
Tredan, O., Galmarini, C. M., Patel, K., & Tannock, I. F. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm135 · Cited by 2,116
Identifying differentially expressed genes using false discovery rate controlling procedures
Reiner, A., Yekutieli, D., & Benjamini, Y. (2003) · Bioinformatics · doi:10.1093/bioinformatics/btf877 · Cited by 1,765
High drug attrition rates—where are we going wrong?
Hutchinson, L., & Kirk, R. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.34 · Cited by 517
Cited by
Personalized medicine: motivation, challenges, and progress
Goetz, L. H., & Schork, N. J. (2018) · Fertility and Sterility · doi:10.1016/j.fertnstert.2018.05.006 · Cited by 976
Emerging Frontiers in Drug Delivery
Tibbitt, M. W., Dahlman, J. E., & Langer, R. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.5b09974 · Cited by 975
Palmer, A. C., & Sorger, P. K. (2017) · Cell · doi:10.1016/j.cell.2017.11.009 · Cited by 642
“Several such technologies are in development, including implantable or microinjection devices to measure in situ drug response in humans (Jonas et al., 2015; Klinghoffer et al., 2015) and drug response profiling on tumor xenografts or biopsies (Hidalgo et al., 2014).”
BackgroundPrecision medicine for cancer with next-generation functional diagnostics
Friedman, A. A., Letai, A., Fisher, D. E., & Flaherty, K. T. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4015 · Cited by 570
Functional precision cancer medicine—moving beyond pure genomics
Letai, A. (2017) · Nature Medicine · doi:10.1038/nm.4389 · Cited by 366
Letai, A., Bhola, P., & Welm, A. L. (2022) · Cancer Cell · doi:10.1016/j.ccell.2021.12.004 · Cited by 281
Engineering and physical sciences in oncology: challenges and opportunities
Mitchell, M. J., Jain, R. K., & Langer, R. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.83 · Cited by 273
Trial Watch: experimental TLR7/TLR8 agonists for oncological indications
Frega, G., Wu, Q., Le Naour, J., Vacchelli, E., Galluzzi, L., Kroemer, G., & Kepp, O. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1796002 · Cited by 108
Multiplexed drug testing of tumor slices using a microfluidic platform
Horowitz, L. F., Rodriguez, A. D., Dereli-Korkut, Z., Lin, R., Castro, K., Mikheev, A. M., Monnat, R. J., Folch, A., & Rostomily, R. C. (2020) · npj Precision Oncology · doi:10.1038/s41698-020-0117-y · Cited by 88
A microfluidic platform for functional testing of cancer drugs on intact tumor slices
Rodriguez, A. D., Horowitz, L. F., Castro, K., Kenerson, H., Bhattacharjee, N., Gandhe, G., Raman, A., Monnat, R. J., Yeung, R., Rostomily, R. C., et al. (2020) · Lab on a Chip · doi:10.1039/c9lc00811j · Cited by 77
An in vivo multiplexed small-molecule screening platform
Grüner, B. M., Schulze, C. J., Yang, D., Ogasawara, D., Dix, M. M., Rogers, Z. N., Chuang, C.-H., McFarland, C. D., Chiou, S.-H., Brown, J. M., et al. (2016) · Nature Methods · doi:10.1038/nmeth.3992 · Cited by 62
Microdissected “cuboids” for microfluidic drug testing of intact tissues
Horowitz, L. F., Rodriguez, A. D., Au-Yeung, A., Bishop, K. W., Barner, L. A., Mishra, G., Raman, A., Delgado, P., Liu, J. T. C., Gujral, T. S., et al. (2021) · Lab on a Chip · doi:10.1039/d0lc00801j · Cited by 62
Adaptive T-cell immunity controls senescence-prone MyD88- or CARD11-mutant B-cell lymphomas
Reimann, M., Schrezenmeier, J., Richter-Pechanska, P., Dolnik, A., Hick, T. P., Schleich, K., Cai, X., Fan, D. N. Y., Lohneis, P., Maßwig, S., et al. (2021) · Blood · doi:10.1182/blood.2020005244 · Cited by 59
Metadata
- Authors
- Klinghoffer, R. A., Bahrami, S. B., Hatton, B. A., Frazier, J. P., Moreno-Gonzalez, A., Strand, A. D., Kerwin, W. S., Casalini, J. R., Thirstrup, D. J., You, S., Morris, S. M., Watts, K. L., Veiseh, M., Grenley, M. O., Tretyak, I., Dey, J., Carleton, M., Beirne, E., Pedro, K. D., Ditzler, S. H., Girard, E. J., Deckwerth, T. L., Bertout, J. A., Meleo, K. A., Filvaroff, E. H., Chopra, R., Press, O. W., & Olson, J. M.
- Venue
- Science Translational Medicine
- Published
- 2015-04-22
- Volume
- 7
- Issue
- 284
- Pages
- 284ra58-284ra58
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W1967783949
- Cited by
- 90
- References
- 6
- FWCI
- 5.46
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.